CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
Adia Nutrition Inc. (OTCQB: ADIA) has successfully uplisted from OTC Pink Sheets to the OTCQB Venture Market in a record-breaking six weeks, compared to the typical 12-16 week timeline. The company also completed SEC Rule 15c2-11 compliance, enhancing transparency and trading liquidity. The uplisting process, completed on May 16, 2025, followed an independent audit with Astra Audit and Advisory LLC on April 1, 2025.
CEO Larry Powalisz highlighted this achievement as part of Adia's strategic vision toward a future Nasdaq Small Cap listing. The company, which specializes in umbilical cord stem cell therapies and premium nutritional products, recently opened its first Florida clinic for regenerative therapies and had its shell risk designation removed.
Adia Nutrition Inc. (OTCQB: ADIA) ha completato con successo il passaggio dalle OTC Pink Sheets al mercato OTCQB Venture in sole sei settimane, un risultato record rispetto alle 12-16 settimane normalmente richieste. L'azienda ha inoltre adempiuto alla conformità alla Regola SEC 15c2-11, migliorando la trasparenza e la liquidità delle negoziazioni. Il processo di uplisting, concluso il 16 maggio 2025, è stato preceduto da un audit indipendente condotto da Astra Audit and Advisory LLC il 1° aprile 2025.
Il CEO Larry Powalisz ha sottolineato questo traguardo come parte della visione strategica di Adia verso una futura quotazione al Nasdaq Small Cap. La società, specializzata in terapie con cellule staminali del cordone ombelicale e prodotti nutrizionali di alta qualità, ha recentemente inaugurato la sua prima clinica in Florida dedicata alle terapie rigenerative e ha ottenuto la rimozione della designazione di rischio shell.
Adia Nutrition Inc. (OTCQB: ADIA) ha logrado con éxito su ascenso desde OTC Pink Sheets al mercado OTCQB Venture en un tiempo récord de seis semanas, frente a las 12-16 semanas habituales. La compañía también completó la conformidad con la Regla 15c2-11 de la SEC, mejorando la transparencia y la liquidez de las operaciones. El proceso de uplisting, finalizado el 16 de mayo de 2025, siguió a una auditoría independiente realizada por Astra Audit and Advisory LLC el 1 de abril de 2025.
El CEO Larry Powalisz destacó este logro como parte de la visión estratégica de Adia hacia una futura cotización en el Nasdaq Small Cap. La empresa, especializada en terapias con células madre del cordón umbilical y productos nutricionales premium, abrió recientemente su primera clínica en Florida para terapias regenerativas y se le eliminó la designación de riesgo shell.
Adia Nutrition Inc. (OTCQB: ADIA)는 일반적으로 12~16주가 소요되는 것과 달리 단 6주 만에 OTC Pink Sheets에서 OTCQB 벤처 마켓으로 성공적으로 상장 승격을 완료했습니다. 회사는 또한 SEC 규칙 15c2-11 준수를 완료하여 투명성과 거래 유동성을 강화했습니다. 2025년 5월 16일에 완료된 이번 상장 승격 과정은 2025년 4월 1일 Astra Audit and Advisory LLC의 독립 감사에 이어 진행되었습니다.
CEO Larry Powalisz는 이 성과를 미래 Nasdaq Small Cap 상장을 향한 Adia의 전략적 비전의 일부로 강조했습니다. 탯줄 줄기세포 치료와 프리미엄 영양 제품을 전문으로 하는 이 회사는 최근 플로리다에 재생 치료를 위한 첫 클리닉을 개설했으며 쉘 리스크 지정도 해제되었습니다.
Adia Nutrition Inc. (OTCQB : ADIA) a réussi à passer des OTC Pink Sheets au marché OTCQB Venture en un temps record de six semaines, contre 12 à 16 semaines en moyenne. La société a également complété la conformité à la règle SEC 15c2-11, améliorant ainsi la transparence et la liquidité des échanges. Le processus d'ascension, finalisé le 16 mai 2025, a suivi un audit indépendant réalisé par Astra Audit and Advisory LLC le 1er avril 2025.
Le PDG Larry Powalisz a souligné cette réussite comme faisant partie de la vision stratégique d'Adia vers une future cotation au Nasdaq Small Cap. La société, spécialisée dans les thérapies à base de cellules souches du cordon ombilical et les produits nutritionnels haut de gamme, a récemment ouvert sa première clinique en Floride dédiée aux thérapies régénératives et a vu la suppression de sa désignation de risque shell.
Adia Nutrition Inc. (OTCQB: ADIA) hat den Aufstieg von den OTC Pink Sheets zum OTCQB Venture Market in rekordverdächtigen sechs Wochen erfolgreich abgeschlossen, verglichen mit den üblichen 12-16 Wochen. Das Unternehmen hat außerdem die SEC-Regel 15c2-11 Compliance erfüllt, was die Transparenz und Handelsliquidität verbessert. Der Uplisting-Prozess, der am 16. Mai 2025 abgeschlossen wurde, folgte auf ein unabhängiges Audit durch Astra Audit and Advisory LLC am 1. April 2025.
CEO Larry Powalisz hob diesen Erfolg als Teil von Adias strategischer Vision für eine zukünftige Notierung am Nasdaq Small Cap hervor. Das Unternehmen, das sich auf Nabelschnur-Stammzelltherapien und hochwertige Ernährungsprodukte spezialisiert hat, eröffnete kürzlich seine erste Klinik in Florida für regenerative Therapien und erhielt die Aufhebung der Shell-Risikobewertung.
- None.
- None.
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT.
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed.
OTCQB Uplisting
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/252376_adiaimage.jpg
The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025.
The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector.
"Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing."
The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them.
Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252376
FAQ
What does Adia Nutrition's (ADIA) uplisting to OTCQB mean for investors?
How long did it take ADIA to complete its OTCQB uplisting process?
What is SEC Rule 15c2-11 compliance and why is it important for ADIA stock?
What are Adia Nutrition's (ADIA) main business segments?
What are ADIA's future plans after the OTCQB uplisting?
